PMID- 15881645
OWN - NLM
STAT- MEDLINE
DCOM- 20050531
LR  - 20201209
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 83
IP  - 3
DP  - 2005
TI  - [Helicobacter pylori infection in patients with chronic hives and asthma].
PG  - 58-61
AB  - Difficulties in treatment of allergic diseases (ADs) are often determined by the 
      fact that the origin of the illness is impossible to establish. Foreign 
      researchers have demonstrated a correlation between Helicobacter pylori (HP) 
      persistence and such conditions as chronic relapsing urticaria (CRLU), Quincke's 
      edema (QO) and respiratory manifestations of allergy (usually bronchial asthma 
      (BA)). HP may participate in the forming of ADs in three possible ways: 1) the 
      bacteria interact with mast cells, and thus are able to initiate mediator 
      liberation; 2) being full antigens, the bacteria themselves are able to cause 
      allergy; 3) the infection process development impairs the barrier function of the 
      alimentary tract mucosa, thus impairing food processing. This creates conditions 
      for allergic food particles to enter bloodstream, which is facilitated by 
      inflammatory lesions of the intestinal tract, protozoal and helminthic invasion, 
      and dysbacteriosis. The aim of the study was to determine how frequently patients 
      with CRU, QO and BA have HP invasion and develop intestinal microflora 
      disbalance, as well as to find out whether there is a correlation between HP 
      infection and alterations in the IgE-system, and establish anti-HP therapy 
      effects, measuring the levels of anti-helicobacter antibody and IgE before and 
      after the treatment. The study revealed HP invasion in 89.2% of patients with 
      chronic ADs; 96.7% of the subjects had disturbances of microbiocenosis; total IgE 
      level correlated with the allergic process activity and anti-helicobacter 
      antibody level; eradicational therapy was more effective when included proton 
      pump inhibitor, clarithromycin and flemoxin than when de-nol, clarithromycin and 
      flemoxin were administered. According to the results of the study, 
      anti-helicobacter therapy allows more effective treatment of patients with 
      relapsing ADs and HP infection.
FAU - Karel'skaia, I A
AU  - Karel'skaia IA
FAU - Ignat'ev, V K
AU  - Ignat'ev VK
LA  - rus
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Enzyme Inhibitors)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - H1250JIK0A (Clarithromycin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antibodies, Bacterial/blood
MH  - Asthma/blood/*complications/immunology
MH  - Chronic Disease
MH  - Clarithromycin/therapeutic use
MH  - Enzyme Inhibitors/therapeutic use
MH  - Feces/microbiology
MH  - Female
MH  - Follow-Up Studies
MH  - Helicobacter Infections/*complications/drug therapy/microbiology
MH  - Helicobacter pylori/*immunology/isolation & purification
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/therapeutic use
MH  - Treatment Outcome
MH  - Urticaria/blood/*complications/immunology
EDAT- 2005/05/11 09:00
MHDA- 2005/06/01 09:00
CRDT- 2005/05/11 09:00
PHST- 2005/05/11 09:00 [pubmed]
PHST- 2005/06/01 09:00 [medline]
PHST- 2005/05/11 09:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 2005;83(3):58-61.